Global Exocrine Pancreatic Insufficiency Market Growth (Status and Outlook) 2023-2029

Global Exocrine Pancreatic Insufficiency Market Growth (Status and Outlook) 2023-2029

Exocrine pancreatic insufficiency (EPI) is an inability of proper digestion of food owing to insufficient levels of digestive enzymes from pancreas.

LPI (LP Information)' newest research report, the “Exocrine Pancreatic Insufficiency Industry Forecast” looks at past sales and reviews total world Exocrine Pancreatic Insufficiency sales in 2022, providing a comprehensive analysis by region and market sector of projected Exocrine Pancreatic Insufficiency sales for 2023 through 2029. With Exocrine Pancreatic Insufficiency sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Exocrine Pancreatic Insufficiency industry.

This Insight Report provides a comprehensive analysis of the global Exocrine Pancreatic Insufficiency landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Exocrine Pancreatic Insufficiency portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Exocrine Pancreatic Insufficiency market.

This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Exocrine Pancreatic Insufficiency and breaks down the forecast by type, by application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Exocrine Pancreatic Insufficiency.

The global Exocrine Pancreatic Insufficiency market size is projected to grow from US$ 1971.6 million in 2022 to US$ 2604.7 million in 2029; it is expected to grow at a CAGR of 4.1% from 2023 to 2029.

EPI is commonly found in humans affected with Shwachman-Diamond Syndrome and cystic fibrosis. EPI is triggered by the progressive loss of pancreatic cells, which generates the digestive enzymes. EPI disturbs the normal growth, life expectancy and immune response. Diarrhoea, Steatorrhea, fatigue and weight loss are the key symptoms of EPI.

This report presents a comprehensive overview, market shares, and growth opportunities of Exocrine Pancreatic Insufficiency market by product type, application, key players and key regions and countries.

Market Segmentation:

Segmentation by type
Therapeutics
Diagnostics

Segmentation by application
Hospitals
Clinics
Others

This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries

The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
Axcan Pharma
Aptalis Pharma
Eli Lilly
Cilian
Nordmark Arzneimittel
Laboratoires Mayoly Spindler

Please note: The report will take approximately 2 business days to prepare and deliver.